3D Medicine's First Independently Developed New Drug Approved For Clinical Use

On January 29, 2020, 3D Medicines announced that the clinical trial application of its self-developed category 1 innovative drug 3D011 has been approved by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration, marking the approval of 3D Medicines Already have the original research ability to research and develop innovative drugs with global intellectual property rights, which has laid a solid foundation for achieving the company’s long-term sustainable development strategic goals.

3D011 Drug Clinical Trial Approval Notice (Picture source 3D Medicine)

3D011 is a class I innovative drug for the treatment of advanced solid tumors. The parent drug has a good inhibitory effect on related kinases. Clinical data has fully proved its good anti-tumor efficacy. The R&D team of 3D Medicine improved its pharmacokinetic properties through prodrug design, thereby reducing its systemic toxicity, and obtained the innovative drug 3D011.

❖ Medicilon’s Synthetic Chemistry Services

Medicilon can undertake the synthesis of special reagents, intermediates and molecular fragments, preparation of standard products, synthesis design and preparation of impurities or metabolites, synthesis of stable isotope internal standards and synthesis of tritiated compounds.

Aim at chemical synthesis through Ibuprofen

Medicilon FTE services & FFS services - flexible and efficient cooperation model

Medicilon Drug Discovery--Opening the Door of Innovative Drugs with Science and Professionalism

Medicilon was fortunate to cooperate with 3D Medicine in the 3D011 research and development project. Under the guidance of 3D Medicine’s R&D team, Medicilon’s pharmaceutical research team helped 3D Medicine overcome the difficulties in the process of drug synthesis and purification and helped it complete the development of APIs.
Medicilon congratulates the phased success of the 3D011 project, and looks forward to cooperating with 3D Medicine and many innovative drug companies in the future to create a thriving and flourishing innovative drugs, and to watch a new chapter in human health!

About 3D Medicine

3D Medicines Inc. is a biomedical company in the stage of advanced clinical development and early commercialization. Adhering to the concept of “helping cancer patients live longer and better”, it aims at the future trend of slowing cancer treatment , Focusing on developing a new generation of differentiated tumor immunotherapy drugs for cancer patients around the world, extending the survival time of cancer patients and improving the quality of life of patients. The company’s product line includes a new generation of biomacromolecule drugs and small molecule chemical drugs, and has a team with international new drug development, registration and commercial operation capabilities.

About Medicilon

Medicilon (stock code: 688202) was established in 2004 and is headquartered in Shanghai. It is committed to providing a full range of preclinical new drug research services for global pharmaceutical companies, research institutions and scientific researchers. Medicilon’s one-stop integrated service helps customers accelerate the development of new drugs with strong project management and more efficient and cost-effective R&D services. The services cover the entire process of preclinical new drug research in medicine, including drug discovery, pharmaceutical research and clinical trials, pre-research. Medicilon grows together with high-quality customers at home and abroad, and provides new drug research and development services to more than 700 customers around the world. Medicilon will continue to base itself on a global perspective, gather Chinese innovation, and contribute to human health!

What is preclinical testing?

In the process of preclinical testing of a compound or biological agent into a drug, the compound involved must go through the testing phase. First, we need to identify potential targets that can treat the disease. Then, a variety of compounds or preparations are screened out. Any compound that has shown potential as a drug for the treatment of this disease needs to be tested for toxicity before clinical testing to reduce the possibility of injury. preclinical testing What is the basis of preclinical testing? According to US Food and Drug Administration (FDA) regulations, a series of tests are required before a new drug is approved for use. In the first stage, basic research determines a hypothetical target for the treatment of a certain disease, and then screens small molecules or biological compounds to discover any substance with the potential to treat the disease. Then, a preclinical research phase followed, before which, as described above, the potential toxicity of the compou

阅读全文

Inventory of the three major in vitro pharmacokinetic research methods

The metabolic properties of a compound are an essential factor in whether or not it can be used as a drug in the clinical setting, so pharmacokinetic studies of newly synthesized compounds are required in drug development. In vitro incubation with liver microsomes, recombinant CYP450 enzyme lines, and in vitro incubation with hepatocytes are some of the more common in vitro drug metabolism methods. 1. In vitro incubation method with liver microsomes The metabolic stability and metabolic phenotypes of candidate compounds in different species of liver microsomes are good predictors of the metabolic properties of compounds in vivo. They are practical tools for evaluating candidate compounds in the pre-development phase of drug development. Liver microsomes include rat liver microsomes, human liver microsomes, canine liver microsomes, monkey liver microsomes, and mouse liver microsomes. In in vitro incubation of the liver, microsomes are the "gold standard" for in vitro d

阅读全文

Novel Parkinson’s Therapies Possible with New Mouse Model

Parkinson's disease (PD) is a neurodegenerative disorder that is marked by the accumulation of the protein, α-synuclein (αS), into clumps known as Lewy bodies, which diminish neural health. Now, researchers from Brigham and Women's Hospital (BWH) report the development of a mouse model to induce PD-like αS aggregation, leading to resting tremor and abnormal movement control. The mouse responds to L-DOPA, similarly to patients with PD. The team's study (“Abrogating Native α-Synuclein Tetramers in Mice Causes a L-DOPA-Responsive Motor Syndrome Closely Resembling Parkinson’s Disease”) on the use of this transgenic mouse model appears in Neuron . “α-Synuclein (αS) regulates vesicle exocytosis but forms insoluble deposits in PD. Developing disease-modifying therapies requires animal models that reproduce cardinal features of PD. We recently described a previously unrecognized physiological form of αS, α-helical tetramers, and showed that familial PD-causing missense mutati

阅读全文

Shanghai Medicilon Inc.

搜索此博客